Literature DB >> 1600341

Idiopathic portal hypertension in a renal transplant patient after long-term azathioprine therapy.

R Lorenz1, M Brauer, M Classen, N Tornieporth, K Becker.   

Abstract

We report the case of a patient with renal insufficiency who was admitted for the evaluation of splenomegaly. He had received a kidney allograft 6 1/2 years ago. Treatment with azathioprine and prednisolone for immunosuppression had been discontinued 1 year before admission. The underlying cause of the splenomegaly appeared to be an idiopathic portal hypertension. Until now, this disease has been described in only 13 kidney transplant patients receiving long-term immunosuppressive therapy with azathioprine. For the first time we demonstrate that azathioprine can cause this chronic liver disease even if the drug has been withdrawn some time before. Therefore, the indication for azathioprine must be considered very carefully.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600341     DOI: 10.1007/bf00227358

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  24 in total

1.  Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation.

Authors:  P G Gerlag; J P van Hooff
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

2.  Liver diseases and hepatic complications in renal transplant patients.

Authors:  A Debure; F Degos; S Pol; C Degott; F Carnot; C Lugassy; M Lacombe; H Kreis
Journal:  Adv Nephrol Necker Hosp       Date:  1988

3.  Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy.

Authors:  H Weitz; J M Gokel; K Loeschke; K Possinger; M Eder
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

4.  Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt. Report of a case and review of the literature.

Authors:  T Eisenhauer; H Hartmann; K W Rumpf; U Helmchen; F Scheler; W Creutzfeldt
Journal:  Digestion       Date:  1984       Impact factor: 3.216

5.  Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?

Authors:  F Liaño; A Moreno; R Matesanz; J L Teruel; C Redondo; F García-Martín; L Orte; J Ortuño
Journal:  Nephron       Date:  1989       Impact factor: 2.847

6.  Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment after kidney transplantation.

Authors:  P G Gerlag; S Lobatto; W M Driessen; P F Deckers; J P Van Hooff; E Schröder; K M Assmann; U J Van Haelst
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

7.  Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients.

Authors:  M I Lorber; C T Van Buren; S M Flechner; C Williams; B D Kahan
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

8.  Azathioprine and hepatic venocclusive disease in renal transplant patients.

Authors:  D A Katzka; S H Saul; D Jorkasky; H Sigal; J C Reynolds; R D Soloway
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

9.  Nonhepatitis B-associated liver disease in a renal transplant population.

Authors:  N W Boyce; S R Holdsworth; D Hooke; N M Thomson; R C Atkins
Journal:  Am J Kidney Dis       Date:  1988-04       Impact factor: 8.860

10.  Liver disease in recipients of long-functioning renal allografts.

Authors:  M R Weir; R L Kirkman; T B Strom; N L Tilney
Journal:  Kidney Int       Date:  1985-11       Impact factor: 10.612

View more
  2 in total

1.  Hepatoportal sclerosis in a child.

Authors:  Nur Arslan; Benal Buyukgebiz; Yesim Ozturk; Samil Hizli; Ozlem Bekem; Ozgül Sagol; Erdener Ozer
Journal:  Eur J Pediatr       Date:  2004-08-17       Impact factor: 3.183

2.  Imaging and Pathological Features of Idiopathic Portal Hypertension and Differential Diagnosis from Liver Cirrhosis.

Authors:  Zhen-Long Zhao; Ying Wei; Tai-Ling Wang; Li-Li Peng; Yan Li; Ming-An Yu
Journal:  Sci Rep       Date:  2020-02-12       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.